These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 36344797)

  • 41. Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma.
    Berger Y; Schuitevoerder D; Vining CC; Alpert L; Fenton E; Hindi E; Liao CY; Shergill A; Catenacci DVT; Polite BN; Eng OS; Turaga KK
    Ann Surg Oncol; 2021 Mar; 28(3):1777-1785. PubMed ID: 32892267
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Utility of Neoadjuvant Chemotherapy for Peritoneal Carcinomatosis Secondary to High-Grade Appendiceal Neoplasms for Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
    Ann Surg Oncol; 2022 Apr; 29(4):2641-2648. PubMed ID: 35022900
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Randle RW; Griffith KF; Fino NF; Swett KR; Stewart JH; Shen P; Levine EA; Votanopoulos KI
    J Surg Res; 2015 Jun; 196(2):229-34. PubMed ID: 25881787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ASO Author Reflections: CRS/HIPEC Cannot be Done-Now what? Systemic Chemotherapy in Mucinous Appendiceal Cancer.
    Baron E; King MC; Gushchin V; Sardi A; Ledakis P
    Ann Surg Oncol; 2022 Oct; 29(11):6590-6591. PubMed ID: 35644859
    [No Abstract]   [Full Text] [Related]  

  • 45. Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix.
    Lopez-Ramirez F; Gushchin V; Sittig M; King MC; Baron E; Nikiforchin A; Nieroda C; Sardi A
    Ann Surg Oncol; 2022 Jun; 29(6):3390-3401. PubMed ID: 35133518
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy Still Indicated in Patients With Extraperitoneal Disease?
    Beal EW; Chen JC; Kim A; Johnston FM; Abbott DE; Raoof M; Grotz TE; Fournier K; Dineen S; Veerapong J; Clarke C; Staley C; Patel SH; Lambert L; Cloyd JM
    J Surg Res; 2022 Sep; 277():269-278. PubMed ID: 35525209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Who Undergoes Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Appendiceal Cancer? An Analysis of the National Cancer Database.
    Byrne RM; Gilbert EW; Dewey EN; Herzig DO; Lu KC; Billingsley KG; Deveney KE; Tsikitis VL
    J Surg Res; 2019 Jun; 238():198-206. PubMed ID: 30772678
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
    Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
    JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience.
    Fung X; Li IC; Chandrakumaran K; Cecil T; Dayal S; Tzivanakis A; Moran B; Mohamed F
    Eur J Surg Oncol; 2022 Jul; 48(7):1614-1618. PubMed ID: 35168851
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Volume-Time Index Is Not an Indicator of Outcome for Patients Undergoing CRS/HIPEC for Treatment of High-Grade Appendiceal Carcinomatosis.
    Dotta DM; Lansom JD; Fisher OM; Fracs NAA; Liauw W; Morris DL
    Anticancer Res; 2019 Dec; 39(12):6813-6817. PubMed ID: 31810947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer.
    Rozich NS; Lewis SE; Chen S; Stewart KE; Stout MB; Dooley WC; Fischer LE; Morris KT
    PLoS One; 2021; 16(4):e0250726. PubMed ID: 33930051
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: an emerging treatment option for advanced goblet cell tumors of the appendix.
    McConnell YJ; Mack LA; Gui X; Carr NJ; Sideris L; Temple WJ; Dubé P; Chandrakumaran K; Moran BJ; Cecil TD
    Ann Surg Oncol; 2014 Jun; 21(6):1975-82. PubMed ID: 24398544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oncologic Risk Stratification Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Carcinomatosis.
    Wagner PL; Austin F; Zenati M; Jaech A; Mavanur A; Ramalingam L; Jones HL; Holtzman MP; Ahrendt SA; Zureikat AH; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2016 May; 23(5):1587-93. PubMed ID: 26744106
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
    Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
    Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of signet ring cells on overall survival in peritoneal disseminated appendix cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Shamavonian R; Lansom JD; Karpes JB; Alzahrani NA; Morris DL
    Eur J Surg Oncol; 2021 Jan; 47(1):194-198. PubMed ID: 33272738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study.
    Powers BD; Felder S; Veerapong J; Baumgartner JM; Clarke C; Mogal H; Staley CA; Maithel SK; Patel S; Dhar V; Lambert L; Hendrix RJ; Abbott DE; Pokrzywa C; Raoof M; Lee B; Johnston FM; Greer J; Cloyd JM; Kimbrough C; Grotz T; Leiting J; Fournier K; Lee AJ; Imanirad I; Dessureault S; Dineen SP
    Ann Surg Oncol; 2020 Dec; 27(13):4883-4891. PubMed ID: 32318945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study.
    Madsen AH; Ladekarl M; Villadsen GE; Grønbæk H; Sørensen MM; Stribolt K; Verwaal VJ; Iversen LH
    Ann Surg Oncol; 2018 Feb; 25(2):422-430. PubMed ID: 29214450
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
    Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
    Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for maximal volume (PCI 39) appendiceal tumours.
    Sarkar A; Lansom J; Dey A; Fisher O; Alzahrani N; Morris DL
    Eur J Surg Oncol; 2021 Jun; 47(6):1406-1410. PubMed ID: 33279358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.